Literature DB >> 28777197

ELABELA Improves Cardio-Renal Outcome in Fatal Experimental Septic Shock.

David Coquerel1, Frédéric Chagnon, Xavier Sainsily, Lauralyne Dumont, Alexandre Murza, Jérôme Côté, Robert Dumaine, Philippe Sarret, Éric Marsault, Dany Salvail, Mannix Auger-Messier, Olivier Lesur.   

Abstract

OBJECTIVES: Apelin-13 was recently proposed as an alternative to the recommended β-adrenergic drugs for supporting endotoxin-induced myocardial dysfunction. Since Apelin-13 signals through its receptor (Apelin peptide jejunum) to exert singular inotropic/vasotropic actions and to optimize body fluid balance, this candidate pathway might benefit septic shock management. Whether the newly discovered ELABELA (ELA), a second endogenous ligand of the Apelin peptide jejunum receptor highly expressed in the kidney, further improves cardio-renal impairment remains unknown. DESIGN, SETTING, AND
SUBJECTS: Interventional study in a rat model of septic shock (128 adult males) to assess the effects of ELA and Apelin-13 on vascular and cardio-renal function. Experiments were performed in a tertiary care University-based research institute.
INTERVENTIONS: Polymicrobial sepsis-induced cardiac dysfunction was produced by cecal ligation puncture to assess hemodynamic efficacy, cardioprotection, and biomechanics under acute or continuous infusions of the apelinergic agonists ELA or Apelin-13 (39 and 15 µg/kg/hr, respectively) versus normal saline.
MEASUREMENTS AND MAIN RESULTS: Apelinergic agonists improved 72-hour survival after sepsis induction, with ELA providing the best clinical outcome after 24 hours. Apelinergic agonist infusion counteracted cecal ligation puncture-induced myocardial dysfunction by improving left ventricular pressure-volume relationship. ELA-treated cecal ligation puncture rats were the only group to 1) display a significant improvement in left ventricular filling as shown by increased E-wave velocity and left ventricular end-diastolic volume, 2) exhibit a higher plasma volume, and 3) limit kidney injury and free-water clearance. These beneficial renal effects were superior to Apelin-13, likely because full-length ELA enabled a distinctive regulation of pituitary vasopressin release.
CONCLUSIONS: Activation of the apelinergic system by exogenous ELA or Apelin-13 infusion improves cardiovascular function and survival after cecal ligation puncture-induced sepsis. However, ELA proved better than Apelin-13 by improving fluid homeostasis, cardiovascular hemodynamics recovery, and limiting kidney dysfunction in a vasopressinergic-dependent manner.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28777197     DOI: 10.1097/CCM.0000000000002639

Source DB:  PubMed          Journal:  Crit Care Med        ISSN: 0090-3493            Impact factor:   7.598


  18 in total

Review 1.  The apelinergic system: a perspective on challenges and opportunities in cardiovascular and metabolic disorders.

Authors:  Eric Marsault; Catherine Llorens-Cortes; Xavier Iturrioz; Hyung J Chun; Olivier Lesur; Gavin Y Oudit; Mannix Auger-Messier
Journal:  Ann N Y Acad Sci       Date:  2019-06-25       Impact factor: 5.691

2.  Is ELABELA a reliable biomarker for hypertensive disorders of pregnancy?

Authors:  Rong Huang; Jing Zhu; Lin Zhang; Xiaolin Hua; Weiping Ye; Chang Chen; Kun Sun; Weiye Wang; Liping Feng; Jun Zhang
Journal:  Pregnancy Hypertens       Date:  2019-06-27       Impact factor: 2.899

Review 3.  Vascular effects of apelin: Mechanisms and therapeutic potential.

Authors:  Amreen Mughal; Stephen T O'Rourke
Journal:  Pharmacol Ther       Date:  2018-05-25       Impact factor: 12.310

4.  ELABELA antagonizes intrarenal renin-angiotensin system to lower blood pressure and protects against renal injury.

Authors:  Chuanming Xu; Fei Wang; Yanting Chen; Shiying Xie; Danielle Sng; Bruno Reversade; Tianxin Yang
Journal:  Am J Physiol Renal Physiol       Date:  2020-03-16

5.  ELABELA plasma concentrations are increased in women with late-onset preeclampsia.

Authors:  Bogdan Panaitescu; Roberto Romero; Nardhy Gomez-Lopez; Percy Pacora; Offer Erez; Felipe Vadillo-Ortega; Lami Yeo; Sonia S Hassan; Chaur-Dong Hsu
Journal:  J Matern Fetal Neonatal Med       Date:  2018-07-22

6.  Fc-apelin fusion protein attenuates lipopolysaccharide-induced liver injury in mice.

Authors:  Huifen Zhou; Rongze Yang; Weimin Wang; Feng Xu; Yue Xi; Robert A Brown; Hong Zhang; Lin Shi; Dalong Zhu; Da-Wei Gong
Journal:  Sci Rep       Date:  2018-07-30       Impact factor: 4.379

Review 7.  Preclinical septic shock research: why we need an animal ICU.

Authors:  Antoine Guillon; Sebastien Preau; Jérôme Aboab; Eric Azabou; Boris Jung; Stein Silva; Julien Textoris; Fabrice Uhel; Dominique Vodovar; Lara Zafrani; Nicolas de Prost; Peter Radermacher
Journal:  Ann Intensive Care       Date:  2019-06-10       Impact factor: 6.925

Review 8.  The role of Elabela in kidney disease.

Authors:  Qian Zheng; Geng Tian; Feng Xu; Xin Ci; Rumei Luan; Linlin Wu; Xuehong Lu
Journal:  Int Urol Nephrol       Date:  2021-03-08       Impact factor: 2.370

9.  The apelinergic system as an alternative to catecholamines in low-output septic shock.

Authors:  David Coquerel; Xavier Sainsily; Lauralyne Dumont; Philippe Sarret; Éric Marsault; Mannix Auger-Messier; Olivier Lesur
Journal:  Crit Care       Date:  2018-01-19       Impact factor: 9.097

10.  Hypertonic sodium lactate improves microcirculation, cardiac function, and inflammation in a rat model of sepsis.

Authors:  Emmanuel Besnier; David Coquerel; Geoffrey Kouadri; Thomas Clavier; Raphael Favory; Thibault Duburcq; Olivier Lesur; Soumeya Bekri; Vincent Richard; Paul Mulder; Fabienne Tamion
Journal:  Crit Care       Date:  2020-06-16       Impact factor: 9.097

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.